CN100358582C - Early senile dementia alpha beta starch spot imaging agent - Google Patents

Early senile dementia alpha beta starch spot imaging agent Download PDF

Info

Publication number
CN100358582C
CN100358582C CNB2005100567889A CN200510056788A CN100358582C CN 100358582 C CN100358582 C CN 100358582C CN B2005100567889 A CNB2005100567889 A CN B2005100567889A CN 200510056788 A CN200510056788 A CN 200510056788A CN 100358582 C CN100358582 C CN 100358582C
Authority
CN
China
Prior art keywords
alpha beta
imaging agent
product
post
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100567889A
Other languages
Chinese (zh)
Other versions
CN1686569A (en
Inventor
张锦明
刘佰里
王武尚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Normal University
Original Assignee
Beijing Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Normal University filed Critical Beijing Normal University
Priority to CNB2005100567889A priority Critical patent/CN100358582C/en
Publication of CN1686569A publication Critical patent/CN1686569A/en
Application granted granted Critical
Publication of CN100358582C publication Critical patent/CN100358582C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention discloses a novel alpha beta-starch plaque imaging agent for presinal dementia, which has the following structure formula: R4-R2-C=N-R1-R3, wherein the R1 and the R2 represent aromatic rings; the R3 is an N-methyl group or an N, or an N-dimethyl group or a methoxyl group, which is positioned on a para position or an ortho position or a meta position of the aromatic ring on one side; the R4 is a group with radioactive nuclein, which is positioned on the para position or the ortho position or the meta position of the aromatic ring on the other side; the positions of the R3 and the R4 can be exchanged. The alpha beta-starch plaque imaging agent is mainly used for raster display for alpha beta-starch plaque of the intravital central nerve, and diagnosis and evaluation for presinal dementia. The affinity constant of the chemical compound of the present invention and alpha beta (1 to 40) aggregation is very high, which can reach n M grade.

Description

Radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent
Technical field
The present invention relates to a kind of medical developer that contains radioactive substance, be specially a kind of early senile dementia alpha beta starch spot imaging agent.
Background technology
One of main neuropathological feature of alzheimer disease (being called for short AD) patient is the senile plaque accumulation, its Main Ingredients and Appearance is amyloid-beta (being called for short A β), A β is one of two macromole marks of AD, also is the goldstandard of clinical postmortem or biopsy diagnosis AD.The stain that pathology detect A β has: (Congo Red, CR), thioflavin-T (Thioflavin-T), thioflavin-S, Chrysamine G (CG) and X-34 etc., these reagent have very high affinity at external and A β to Congo red.If use the radioisotope labeling mentioned reagent, and can effectively break through blood brain barrier (be called for short BBB) and enter brain, just can adopt SPECT or PET technology, carry out senile plaque distribution and quantitative in AD patient's brain in body, visual detection, can improve the early diagnostic rate of AD and differentiate accuracy rate, and can to patient AD by stages, be that the therapeutic scheme (as reducing the A β etc. that A β precursor protein generated, suppressed the generation of A β and gathers, removes generation) of target spot and the research of medicine etc. provide effective evaluation methodology at A β.
The advantage of nuclear medicine image is to have the dyeing of unique pathology or biochemical bonded reagent is made developer with radioisotope labeling, helps disease at body, noninvasive specific diagnosis.Directly,, be not easy to penetrate BBB owing to divide subclass big with radioisotope labeling CG class.In recent years reported in literature the improvement labels of several classes to above chemical compound, obtained certain achievement at zoopery, external autography and preliminary clinicing aspect.
The first kind is 18F-FDDNP, it is that one roughly the same ibuprofen, naproxen chemical constitution are similar, the competition binding site is different from the chemical compound (Agdeppa ED, Neuroscience 117 (2003) 723-730) of Congo red (CG) and thioflavin (Thioflavine T) when combining with the A beta plaque.
Figure C20051005678800031
FDDNP DDNP structural formula
This chemical compound has been used for the diagnosis of clinical AD, patient's AD at present 18The F-FDDNP video picture is concentrated and the low metabolism position consistency of FDG, and the normal control group does not have and concentrates.This developer deficiency is that the injection back is slower from the removing in normal brain activity district.
The second class developer is benzothiophene kind and derivant thereof, is very similar compounds of a class and thioflavin-T (Thioflavin-T) chemical constitution, 125I or 18F, 11The BAT compounds and the A β of C labelling have good affinity, wherein 11The Ki=10nM of the BAT of C labelling (Mathis CA, Bioorg ﹠amp; Medic Chemlett, 2002,12:295-298), 11C-6-0H-BAT is at the clinical preliminary identification that obtains.The characteristics of this compounds are that two aromatic rings of connection are First Five-Year Plan unit's heterocycle, wherein have one for two keys (structural formula as follows), by two keys electron cloud on the aromatic ring of both sides are interacted.Remove soon behind such compound injection of positron radionuclide labelling, the video picture of A beta plaque is clear, is suitable for the diagnosis of clinical early stage AD.But the chemical compound normal brain activity of iodine labeling is removed slow, in order to improve from the removing in normal brain activity district, change S into O, become IBOX, though obviously bring up to 0.8nM with the affinity of A β 1-40, the chemical compound of iodine labeling is still removed slow from the normal brain activity district, the 2min/60min ratio is 1 (Zhuang ZP, Nucl Med Biol, 2001,887-894).Change O into N, increase a pair of key simultaneously, become IMPY, though drop to 15nM with combining of A β, but obviously having increased normal brain activity and blood behind the iodine labeling removes, the 2min/60min ratio is 12, increased target this than (Kung MP, 2002, Brain Research, 2002,202-210), its clinical value needs further checking.
Figure C20051005678800041
Benzothiazoles IBOX class IMPY class
The 3rd class developer is the simplification of second class.Between two aromatic rings, the simplest is directly to be connected into biphenyl, owing to lose the effect of two keys, influence between two aromatic rings and diminish, and A β affinity decline (between 17~100nM).Further modify the key between two phenyl ring, make the increasing that influences each other between the aromatic rings, connect with five-membered ring, and the one-tenth fluorenes (Lee CW, Nucl Med Biol, 2003:573-580).As long as iodine labeling in place, can reach the Ki (0.92nM) higher with A β, but the fluorenes class of iodine labeling is unhappy from the removing of normal brain activity district, and the 2min/60min ratio is 1.57.
Benzene dienes fluorenes class biphenyl class
In order to improve the removing in normal brain activity district, keeping simultaneously with A β has higher affinity, use carbon-carbon double bond between two aromatic rings, influencing each other between the increase aromatic ring, noval chemical compound be the benzene diene (Kung HF, J AmChem Soc, 2001,123:12740-41).Keep higher level with the affinity costant of A β, reach 1.2nM.With 11The benzene diene of C labelling is 3.8 at normal brain activity district 60min/2min ratio, and external autography shows, 11A β has obvious the combination in the benzene dienes of C labelling and the model mouse brain, target this than higher (Ono M, Nucl MedBiol, 2003,30:565).The benzene diene is a class CNS speckle more likely developer.
Summary of the invention
The invention provides a kind of radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, this developer is used for the video picture of the nervus centralis A β-starch speckle of live body, can diagnose and estimate dementia senilis.
The general structure of this radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent is as follows:
R4-R2-C=N-R1-R3
R1 wherein, R2 is expressed as phenyl ring, naphthols or biphenyl; R3 is in the para-position of a side aromatic ring, is N-methyl or N, N-dimethyl or methoxyl group; R4 is in the para-position or an ortho position or a position of opposite side aromatic ring, for-O 11CH 3,-NH 11CH 3,- 18F or- 125The I group; R3 and R4 position are interchangeable.
Aforesaid radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, wherein when R3 was methoxyl group, carbon can be radioactive carbon-11 on this group.
The three kinds of chemical compounds belonging to above-mentioned developer and the affinity costant Ki of starch protein A β (1-40) aggregation are measured, measure used A β (1-40) aggregation and 125I-TZDM, its measuring method is as follows:
Get A β (1-40) aggregation (final analysis concentration is 10-50nM) of 50 μ L, add 50 μ L's 125I-TZDM (100,000 countings/min), add the competitor of 50 μ L, and final volume is diluted to 1mL.Place after 3 hours under the room temperature and separate with cell harvestor, diffusion barrier is a Whatman GF/B filter membrane, and with counting on γ-counter measures film, the Ki result who calculates competitor is as follows:
Compound K i (nM)
Figure C20051005678800051
2.65
Figure C20051005678800052
12.7
Figure C20051005678800061
10.32
This shows that the affinity costant of these three chemical compounds and A β (1-40) aggregation is very high, reaches the nM level, all can become the diagnostic agent and the treatment therapeutic evaluation agent of presenile dementia.
The specific embodiment
Embodiment one 11The synthesizing hydroxyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the para-aminophenol of 1.5g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.77g, and productive rate is 89%.H?NMR(500MHZ,DMSO,δ):3.0(6H),6.77(4H),7.10(2H),7.71(2H),8.39(1H),9.3(1H)。
Figure C20051005678800062
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to hydroxyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 73%.
Figure C20051005678800063
Embodiment two 11Hydroxyl Schiff bases developer is synthetic between the C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the 3-amino-phenol of 1.5g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.5g, and productive rate is 81%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.62(2H),6.7(2H),6.8(1H),7.10(1H),7.44(2H),8.9(1H)。
Figure C20051005678800071
Radioactive label:
Take by weighing 1mg to N, N dimethyl, a hydroxyl Schiff alkali are dissolved among the 0.4mlDMSO, add 2N NaOH 10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 70%.
Embodiment three 11Synthesizing of the naphthols Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds 5-amino-1-naphthols of 2.15g again, refluxes 3 hours.A large amount of brown precipitations are arranged, filtration, drying, the crystallization that the 1.7g that obtains is brown, productive rate is 50%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.6(3H),7.2(1H),7.3(2H),7.4(3H),8.1(H),9.1(1H)。
Figure C20051005678800073
Radioactive label:
Take by weighing 1mg to N, N dimethyl, naphthols Schiff alkali are dissolved among the 0.4mlDMSO, add 2NNaOH 10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 75%.
Figure C20051005678800081
Embodiment four 11Synthesizing of the biphenyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds 2-amido-4-benzene-phenol of 2.47g again, refluxes 3 hours.The precipitation that a large amount of whites are arranged, filtration, drying, the crystallization of the 1.37g white that obtains, productive rate is 36%.HNMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.62(2H),6.8(H),7.22(1H),7.3(2H),7.32(2H),7.44(2H),7.48(2H),8.8(1H)。
Figure C20051005678800082
Radioactive label:
Take by weighing 1mg to N, N dimethyl diphenyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 23%.
Figure C20051005678800083
Embodiment five 11Synthetic (the N-C place-exchange) to hydroxyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.2g to N, the N dimethylaniline is dissolved in the 30ml dehydrated alcohol, adds the para-aminophenol of 1.2g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.1g, and productive rate is 87%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.0(H),6.60(2H),6.76(2H),7.10(2H),7.52(2H),9.2(1H)。
Figure C20051005678800091
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to hydroxyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 75%.
Figure C20051005678800092
Embodiment six 11The synthesizing amido Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing the p-phenylenediamine (PPD) of 1.0g, be dissolved in the 15ml dehydrated alcohol, reflux.Slowly drip the N to 1.2g in solution, N dimethylbenzaldehyde (alcoholic solution) adds in 90min, refluxes 2 hours again.A large amount of xanchromatic precipitations are arranged, and filtration, drying obtain the flaxen thick product of 0.6g.Separate with lamellae, ethyl acetate and normal hexane are made mobile phase, obtain the 0.5g product.H?NMR(500MHZ,DMSO,δ):3.0(6H),4.2(2H),6.5(2H),6.77(2H),7.2(2H),7.44(2H),9.3(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to amido Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: and acetonitrile (71O: 290V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 61%.
Figure C20051005678800094
Embodiment seven 11The methoxyl group of C labelling is to synthesizing of amido Schiff bases developer
Synthesizing of precursor:
Take by weighing the p-phenylenediamine (PPD) of 1.0g, be dissolved in the 15ml dehydrated alcohol, reflux.In solution, slowly drip P-methoxybenzal-dehyde (alcoholic solution), in 90min, add, refluxed again 2 hours 1.1g.Xanchromatic precipitation is arranged, and filtration, drying obtain the xanchromatic thick product of 0.5g.Separate with lamellae, ethyl acetate and normal hexane are made mobile phase, obtain the 0.45g product.H?NMR(500MHZ,DMSO,δ):3.7(3H),4.0(2H),6.5(2H),6.80(2H),7.0(2H),7.51(2H),9.3(1H)。
Figure C20051005678800101
Radioactive label:
The methoxyl group that takes by weighing 1mg is dissolved among the 0.4mlDMSO amido Schiff alkali, adds 2N NaOH10 μ L.In this solution, feed 11CH 3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 58%.
Carbon on this developer methoxyl group can be radioactive carbon-11, is used for video picture simultaneously.
Embodiment eight 18Synthesizing of the para-position Schiff bases developer of F labelling
Synthesizing of precursor:
Take by weighing 1.19g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the paranitroanilinum of 1.1g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, filtration, drying, ethyl alcohol recrystallization obtains the 1.35g product, and productive rate is 65%.H?NMR(500MHZ,DMSO,δ):3.05(6H),6.60(2H),6.80(2H),7.69(2H),7.95(2H),9.67(1H)。
Figure C20051005678800103
Radioactive label:
Accelerator-produced 18F -Ion after QMA absorption by the K2.2.2/K of 1.5ml 2CO 3The acetonitrile solution eluting is gone into reaction tube, the DMSO solution that after secondary removes acetonitrile, adds the nitro precursor that contains 2mg-3mg, behind reaction 10min under 130 ℃, cooling is after adding 10ml water and residue are mixed, and the startup negative pressure enters waste liquid bottle with liquid in the reaction bulb through the C-18 post.Thick product is attracted on the C-18 post.Divide three times 15ml water to be sucked waste liquid bottle through negative pressure, with K2.2.2 and the DMSO eluting that remains on the C-18.Again threeway is switched to the product receiving flask, add 1ml ethanol receiving flask is gone in the product drip washing on the C-18 post.Add an amount of normal saline,, obtain after aseptic filter membrane 18F-N, N dimethyl, to fluorine Schiff alkali.Mark rate is 25%.
Figure C20051005678800111
Embodiment nine 18Synthesizing of the ortho position Schiff bases developer of F labelling
Synthesizing of precursor:
Take by weighing 1.19g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the ortho-nitraniline of 1.1g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, filtration, drying, ethyl alcohol recrystallization obtains the 1.12g product, and productive rate is 42%.H?NMR(500MHZ,DMSO,δ):3.0(6H),6.62(2H),7.44(2H),7.52(2H),7.7(2H),8.21(H),8.39(1H)。
Radioactive label:
Accelerator-produced 18F -Ion after QMA absorption by the K2.2.2/K of 1.5ml 2CO 3The acetonitrile solution eluting is gone into reaction tube, after secondary removes acetonitrile, add contain 2mg-3mg between the DMSO solution of nitro precursor, behind reaction 10min under 130 ℃, cooling is after adding 10ml water and residue are mixed, and the startup negative pressure enters waste liquid bottle with liquid in the reaction bulb through the C-18 post.Thick product is attracted on the C-18 post.Divide three times 15ml water to be sucked waste liquid bottle through negative pressure, with K2.2.2 and the DMSO eluting that remains on the C-18.Again threeway is switched to the product receiving flask, add 1ml ethanol receiving flask is gone in the product drip washing on the C-18 post.Add an amount of normal saline,, obtain after aseptic filter membrane 18F-N, N dimethyl, adjacent fluorine Schiff alkali.Mark rate is 18%.
Figure C20051005678800121
Embodiment ten 125Synthesizing of the Schiff bases developer of I labelling
Synthesizing of precursor:
Take by weighing 298mg to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the para-bromoaniline of 344mg again, refluxes 3 hours.Remove ethanol, filtration, drying, ethyl alcohol recrystallization obtains the 0.4g product, productive rate 65%.Fusing point: 136 ℃, H NMR (500MHZ, DMSO, δ): 2.92 (6H), 6.41 (2H), 7.05 (2H), 7.6 (2H), 9.57 (H).
Figure C20051005678800122
Get 52mg to bromine Schiff alkali, with the Pd (Ph of 20mg 3P) 4Be dissolved in the 12ml triethylamine solution, 90 ℃ of reactions 12 hours.Desolventize,, obtain the precursor of 20mg with TLC method purification.
Figure C20051005678800123
Radioactive label:
Prepare the Xi Dingji precursor alcoholic solution of 50 μ g/50 μ L, add an amount of Na 125I solution is regulated PH, and room temperature is reaction 10min down, adds the NaHSO of 100 μ L 4Neutralization.Directly use ethyl acetate extraction, dry up, the dissolving of 10% ethanol normal saline solution.
Figure C20051005678800124

Claims (2)

1. radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, its general structure is as follows:
R4-R2-C=N-R1-R3
R1 wherein, R2 is expressed as phenyl ring, naphthols or biphenyl; R3 is in the para-position of a side aromatic ring, is N-methyl or N, N-dimethyl or methoxyl group; R4 is in the para-position or an ortho position or a position of opposite side aromatic ring, for-O 11CH 3,-NH 11CH 3,- 18F or- 125The I group; R3 and R4 position are interchangeable.
2. radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent as claimed in claim 1, it is characterized in that: when R3 was methoxyl group, carbon can be radioactive carbon-11 on this group.
CNB2005100567889A 2005-03-25 2005-03-25 Early senile dementia alpha beta starch spot imaging agent Expired - Fee Related CN100358582C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100567889A CN100358582C (en) 2005-03-25 2005-03-25 Early senile dementia alpha beta starch spot imaging agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100567889A CN100358582C (en) 2005-03-25 2005-03-25 Early senile dementia alpha beta starch spot imaging agent

Publications (2)

Publication Number Publication Date
CN1686569A CN1686569A (en) 2005-10-26
CN100358582C true CN100358582C (en) 2008-01-02

Family

ID=35304611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100567889A Expired - Fee Related CN100358582C (en) 2005-03-25 2005-03-25 Early senile dementia alpha beta starch spot imaging agent

Country Status (1)

Country Link
CN (1) CN100358582C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104178132B (en) * 2014-07-30 2017-01-25 四川大学 Fluorescent compound and application thereof in medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266884A1 (en) * 2000-03-22 2002-12-18 BF Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266884A1 (en) * 2000-03-22 2002-12-18 BF Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same

Also Published As

Publication number Publication date
CN1686569A (en) 2005-10-26

Similar Documents

Publication Publication Date Title
ES2620177T3 (en) Imaging agents and their use for in vivo diagnosis of neurodegenerative diseases, particularly Alzheimer's disease and derived diseases
Ono et al. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
MX2012009174A (en) Methods and apparatus for synthesizing imaging agents, and intermediates thereof.
US20090041663A1 (en) Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
NO330176B1 (en) Amyloid Binding Compounds, Methods of Preparation and Use, Pharmaceutical Composition for In Vivo Imaging and Use thereof
CN104159890A (en) Compositions, methods, and systems for the synthesis and use of imaging agents
JP2021513979A (en) Chemical conjugates of Evans blue derivatives and their use as radiation therapy and contrast agents to target prostate cancer
Wu et al. Dibenzothiazoles as novel amyloid-imaging agents
Cui et al. Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for β-amyloid plaques in Alzheimer’s disease
CN102180780A (en) Indenone derivative and applications thereof as developing agent and aggregation inhibitor of amyloid protein deposit and neurofibrillary tangle
Serdons et al. Synthesis of 18F-labelled 2-(4′-fluorophenyl)-1, 3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C] PIB
Lee et al. Dimethylamino-fluorenes: ligands for detecting β-amyloid plaques in the brain
Fuchigami et al. Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT
Ono et al. 18F-labeled flavones for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
JP6840666B2 (en) New anthranilic acid derivative
EP2198040B1 (en) In vivo imaging of myelin
US20090123373A1 (en) Amyloid-imaging agents
US20140336503A1 (en) Radiolabeled biomarkers for osteoclast activation and related methods thereof
CN102557969A (en) Cyclic ketone derivatives and applications thereof as developers and aggregation inhibitors of amyloid protein sediments and neurofibrillary tangles
CN100358582C (en) Early senile dementia alpha beta starch spot imaging agent
EP2711026A1 (en) Radioactive fluorine-labeled quinoxaline compound
CN101020698A (en) Benzothiazole aniline compound marked with Tc-99m and its prepn process and application
CN102432529B (en) Preparation method of styryl pyridine disulfide dinitrogen derivative
Watanabe et al. Synthesis and biological evaluation of radioiodinated 2, 5-diphenyl-1, 3, 4-oxadiazoles for detecting β-amyloid plaques in the brain
CN101888992A (en) Contrast medium

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee